Google
SXTP — 60 DEGREES PHARMACEUTICALS, INC. COMMON STOCK (Healthcare >> Biotechnology)
SXTP FAQ
What is SXTP's ROE?
60 DEGREES PHARMACEUTICALS, INC. COMMON STOCK reports a Return on Equity (ROE) of -157.00%.
What is SXTP's dividend yield?
60 DEGREES PHARMACEUTICALS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is SXTP's Deepscope Quality Score?
Deepscope rates SXTP's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SXTP?
Deepscope's AI Timing Score for SXTP is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SXTP belong to?
60 DEGREES PHARMACEUTICALS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.38
Price
-0.01
(-0.72%)
Day Change
|
|
|---|
SXTP, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 67 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.38 |
| PBV / Sector |
0.80 / 4.79
GREAT
|
| Earning Per Share | -2.77 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
0.08 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-11 09:54:47 |
| Symbol | SXTP |
| Name | 60 DEGREES PHARMACEUTICALS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 2.66 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3.78 / 8,963.32 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1025 Connecticut Avenue NW, Washington, DC, United States, 20036
Phone: 202 327 5422
Website: https://www.60degreespharma.com
Sector: Healthcare >> Biotechnology
Description: 60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
